Results 61 to 70 of about 4,076 (204)

The burden of the postictal state in epilepsy: A prospective, single‐center observational cohort study

Epileptic Disorders, EarlyView.
Abstract Objective The postictal state is a major yet underrecognized component of the epilepsy burden. We aimed to develop a structured patient‐reported instrument to quantify postictal recovery, characterize its multidimensional burden, and identify demographic, clinical, psychiatric, and treatment‐related factors associated with postictal severity ...
Ionuț‐Flavius Bratu, Agnès Trébuchon, Fabrice Bartolomei   +2 more
wiley   +1 more source

Table_2_Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery.xlsx

, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Lise Heylen (11561266), Patrice Godard (3476651), Yifan Zhang (119570), Michèle Partoens (12620839), Aleksandra Siekierska (11561278), Rafal M. Kaminski (12620842), Peter A. M. de Witte (11561275), James D. Mills (9418733), Michel Gillard (261248)   +8 more
core   +1 more source

In Silico and In Vivo: Evaluating the Therapeutic Potential of Kaempferol, Quercetin, and Catechin to Treat Chronic Epilepsy in a Rat Model

Frontiers in Bioengineering and Biotechnology, 2021
Recently, alternative therapies are gaining popularity in the treatment of epilepsy. The present study aimed to find out the antiepileptic potential of quercetin, catechin, and kaempferol.
Hammad Ahmed, Hammad Ahmed, Mahtab Ahmad Khan, Syed Awais Ali Zaidi, Sajjad Muhammad, Sajjad Muhammad   +5 more
doaj   +1 more source

Acute effects of anti‐seizure medications on network level dynamics: A systematic comparison using multielectrode arrays

Epilepsia, EarlyView.
Abstract Objective A multi‐electrode array (MEA) is a powerful extracellular recording technique for long‐term monitoring of neuronal network activity. In recent years, MEA‐based assays have been applied increasingly to evaluate drug efficacy and neurotoxicity, including the assessment of anti‐seizure medications (ASMs). However, systematic comparisons
Griselda Marku, Lena Gschossmann, Kerstin Hallmann, Heinz Beck, Kunihiko Araki   +4 more
wiley   +1 more source

Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease

NeuroImage, 2021
Purpose: 11C-UCB-J PET imaging, targeting synaptic vesicle glycoprotein 2A (SV2A), has been shown to be a useful indicator of synaptic density in Alzheimer's disease (AD).
Yihuan Lu, Takuya Toyonaga, Mika Naganawa, Jean-Dominique Gallezot, Ming-Kai Chen, Adam P. Mecca, Christopher H. van Dyck, Richard E. Carson   +7 more
doaj   +1 more source

Status epilepticus: Updates on mechanisms and treatments

Epilepsia Open, EarlyView.
Abstract Status epilepticus (SE) consists of prolonged, self‐sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super‐refractory SE.
Suchitra Joshi, Jaideep Kapur
wiley   +1 more source

Shared molecular pathways in pediatric genetic epilepsies: Insights from a single‐center cohort of 80 patients

Epilepsia Open, EarlyView.
Abstract Objective Genetic epilepsies in childhood are highly heterogeneous, and approaches to identify shared biological mechanisms across distinct genetic etiologies remain limited. We aimed to investigate whether genes associated with pediatric genetic epilepsies in our heterogeneous cohort converge on common functional pathways.
Laura Hecher, Mathias Woidy, Franziska Plein, Tatjana Bierhals, Leonie von Elsner, Theresia Herget, Maja Hempel, Fanny Kortüm, Lev Grinstein, Julia V. Cramer, Jessika Johannsen, Jonas Denecke   +11 more
wiley   +1 more source

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam [PDF]

Proceedings of the National Academy of Sciences, 2004
Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy. The LEV-binding site is enriched in synaptic vesicles, and photoaffinity labeling of purified synaptic vesicles confirms that it has an apparent ...
Berkley A, Lynch, Nathalie, Lambeng, Karl, Nocka, Patricia, Kensel-Hammes, Sandra M, Bajjalieh, Alain, Matagne, Bruno, Fuks   +6 more
openaire   +2 more sources

Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer’s disease

Alzheimer’s Research & Therapy
Background Previous studies have demonstrated that early intervention was the best plan to inhibit the progression of Alzheimer’s disease (AD), which relied on the discovery of early diagnostic biomarkers. In this study, synaptic vesicle glycoprotein 2 A
Xiaoling Wang, Xiaomin Zhang, Jing Liu, Jingjing Zhang, Congcong Liu, Yuting Cui, Qiao Song, Yuli Hou, Yaqi Wang, Qian Zhang, Yingzhen Zhang, Yujian Fan, Jianping Jia, Peichang Wang   +13 more
doaj   +1 more source

Synaptic vesicle protein 2A regulates mossy fiber sprouting in a drug-resistant epilepsy rat model via laminin α5/integrin β1

Brain Research Bulletin
Drug-resistant epilepsy (DRE) is frequently characterized by pathological mossy fiber sprouting (MFS), which is a defining indicator of aberrant synaptic remodeling within the hippocampus.
Yongfei Shi, Yi Xu, Yinlin Hu, Langtao Liu, Chen Li, Siyin Ren, Guofeng Wu, Likun Wang   +7 more
doaj   +1 more source